{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T10:37:17Z","timestamp":1777631837090,"version":"3.51.4"},"reference-count":84,"publisher":"Annual Reviews","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Annu. Rev. Med."],"published-print":{"date-parts":[[2000,2]]},"abstract":"<jats:p> \u25aa Abstract\u2002 The inherited hypercoagulable states can be divided into those that are common and associated with a modest risk of thrombosis (i.e. factor V Leiden and G20210A prothrombin gene) and those that are uncommon but asssociated with a high risk of thrombosis. There is no convincing evidence that, independent of other clinical factors, the presence of factor V Leiden or the prothrombin gene mutation should influence the use of primary prophylaxis or the duration of anticoagulant therapy following an episode of thrombosis. Indrect evidence sugests that the presence of antithrombin, protein C deficiency, or protein S deficiency justifies avoiding additional risk factors for thrombosis, such as estrogen therapy, and justifies use of more aggressive primary prophylaxis when additional risk factors cannot readily be avoided (e.g. pregnancy). The presence of one of these three abnormalities also favors more prolonged anticoagulant therapy following venous thrombosis. However, their presence or absence appears to have less influence on the risk of recurrent venous thromboembolism than whether thrombosis was provoked by a major reversible risk factor, such as surgery. <\/jats:p>","DOI":"10.1146\/annurev.med.51.1.169","type":"journal-article","created":{"date-parts":[[2002,7,27]],"date-time":"2002-07-27T11:40:39Z","timestamp":1027770039000},"page":"169-185","source":"Crossref","is-referenced-by-count":92,"title":["Management of Patients with Hereditary Hypercoagulable Disorders"],"prefix":"10.1146","volume":"51","author":[{"given":"C.","family":"Kearon","sequence":"first","affiliation":[{"name":"McMaster Clinic, Henderson General Hospital, Hamilton, Ontario L8V 1C3, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Crowther","sequence":"additional","affiliation":[{"name":"McMaster Clinic, Henderson General Hospital, Hamilton, Ontario L8V 1C3, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Hirsh","sequence":"additional","affiliation":[{"name":"McMaster Clinic, Henderson General Hospital, Hamilton, Ontario L8V 1C3, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"22","reference":[{"key":"b1","first-page":"516","volume":"13","year":"1965","journal-title":"Thromb. Diath. Haemorrh."},{"key":"b2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI110385"},{"key":"b3","doi-asserted-by":"publisher","DOI":"10.1172\/JCI111632"},{"key":"b4","doi-asserted-by":"crossref","unstructured":"Dahlback B, Carlsson M, Svensson PJ. 1993. Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C: predication of a cofactor to activated protein C.Proc. Natl. Acad. Sci. USA90:1004\u20138","DOI":"10.1073\/pnas.90.3.1004"},{"key":"b5","doi-asserted-by":"publisher","DOI":"10.1038\/369064a0"},{"key":"b6","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V88.10.3698.bloodjournal88103698"},{"key":"b7","doi-asserted-by":"crossref","unstructured":"Haverkate F, Samama M. 1995. Familial dysfibrinogenemia and thrombophilia report on a study of the SSC subcommittee on fibrinogen.Thromb. Haemost.73(1):151\u201361","DOI":"10.1055\/s-0038-1653741"},{"key":"b8","doi-asserted-by":"crossref","unstructured":"Van den Belt AGM, Huisman MV, Hirsh J. 1996. Familial thrombophilia: a review analysis.Clin. Appl. Thromb. Hemost.2(4):227\u201336","DOI":"10.1177\/107602969600200402"},{"key":"b9","doi-asserted-by":"publisher","DOI":"10.1055\/s-0037-1614438"},{"key":"b10","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(95)90166-3"},{"key":"b11","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-130-8-199904200-00004"},{"key":"b12","doi-asserted-by":"crossref","unstructured":"Mateo J, Oliver A, Borrell M, et al. 1997. Laboratory evaluation and clinical characteristics of 2,132 consecutive unselected patients with venous thromboembolism\u2014results of the Spanish multicentric study on thrombophilia (EMET-study).Thromb. Haemost.77:444\u201351","DOI":"10.1055\/s-0038-1655986"},{"key":"b13","doi-asserted-by":"publisher","DOI":"10.1055\/s-0037-1615137"},{"key":"b14","doi-asserted-by":"publisher","DOI":"10.1055\/s-0037-1614442"},{"key":"b15","doi-asserted-by":"crossref","unstructured":"Lane DA, Mannucci PM, Bauer KA, et al. 1996. Inherited thrombophilia: part 2.Thromb. Haemost.76(6):824\u201334","DOI":"10.1055\/s-0038-1650673"},{"key":"b16","doi-asserted-by":"crossref","unstructured":"Lane DA, Mannucci PM, Bauer KA, et al. 1996. Inherited thrombophilia: part 1.Thromb Haemost.76 (5):651\u201362","DOI":"10.1055\/s-0038-1650638"},{"key":"b17","doi-asserted-by":"crossref","unstructured":"Lane DA, Olds RJ, Boisclair M, et al. 1993. Antithrombin III mutation database: first update.Thromb. Haemost.70:361\u201369","DOI":"10.1055\/s-0038-1649581"},{"key":"b18","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.1994.tb04878.x"},{"key":"b19","doi-asserted-by":"crossref","unstructured":"Meade TW, Dyer S, Howarth DJ. 1990. Antithrombin III and procoagulant activity: sex differences and effects of the menopause.Br. J. Haematol.74:77\u201381","DOI":"10.1111\/j.1365-2141.1990.tb02541.x"},{"key":"b20","doi-asserted-by":"crossref","unstructured":"Finazzi G, Caccia R, Barbui T. 1987. Different prevalence of thromboembolism in the subtypes of congenital antithrombin III deficiency: review of 404 cases.Thromb. Haemost.58:1094","DOI":"10.1055\/s-0038-1646063"},{"key":"b21","first-page":"13","volume":"24","year":"1998","journal-title":"Semin. Thromb. Haemost."},{"key":"b22","doi-asserted-by":"crossref","unstructured":"Hirsh J, Piovella F. 1989. Congenital antithrombin III deficiency.Am. J. Med.87:34\u201338S (Suppl.)","DOI":"10.1016\/0002-9343(89)80529-7"},{"key":"b23","doi-asserted-by":"publisher","DOI":"10.1055\/s-0038-1653730"},{"key":"b24","doi-asserted-by":"crossref","unstructured":"Miletich J, Sherman L, Broze G. 1987. Absence of thrombosis in subjects with heterozygous protein C deficiency.N. Engl. J. Med.317(16):991\u201396","DOI":"10.1056\/NEJM198710153171604"},{"key":"b25","doi-asserted-by":"publisher","DOI":"10.1016\/0140-6736(93)90003-Y"},{"key":"b26","doi-asserted-by":"crossref","unstructured":"Heijboer H, Brandjes PM, Buller HR, et al. 1990. Defiencies of coagulation\u2014 inhibiting and fibrinolytic proteins in outpatients with deep-vein thrombosis.N. Engl. J. Med.323:\u2013 1512\u201316","DOI":"10.1056\/NEJM199011293232202"},{"key":"b27","doi-asserted-by":"crossref","unstructured":"Koster T, Rosendaal FR, Bri\u00ebt E, et al. 1995. Protein C deficiency in a controlled series of unselected outpatients: an infrequent but clear risk factor for venous thrombosis (Leiden thrombophilia study).Blood85:2756\u201361","DOI":"10.1182\/blood.V85.10.2756.bloodjournal85102756"},{"key":"b28","doi-asserted-by":"crossref","unstructured":"Koster T, Rosendaal FR, de Ronde H, et al. 1993. Venous thrombosis due to poor anticoagulant response to activated protein C: Leiden thrombophilia study.Lancet342:1503\u20136","DOI":"10.1016\/S0140-6736(05)80081-9"},{"key":"b29","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199504063321403"},{"key":"b30","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-128-1-199801010-00003"},{"key":"b31","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(95)91803-5"},{"key":"b32","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9343(96)00198-2"},{"key":"b33","doi-asserted-by":"crossref","unstructured":"Ridker PM, Miletich JP, Hennekens CH, Buring JE. 1997. Ethnic distribution of factor V Leiden in 4047 men and women: implications for venous thromboembolism screening.JAMA277:1305\u20137","DOI":"10.1001\/jama.277.16.1305"},{"key":"b34","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V91.4.1135"},{"key":"b35","doi-asserted-by":"publisher","DOI":"10.1016\/0735-1097(95)00508-0"},{"key":"b36","doi-asserted-by":"crossref","unstructured":"Tosetto A, Missiaglia E, Gatto E, Rodeghiero F. 1997. The VITA project: phenotype resistance to activated protein C and FV Leiden mutation in the general population.Thromb. Haemost.78:859\u2013 63","DOI":"10.1055\/s-0038-1657642"},{"key":"b37","doi-asserted-by":"publisher","DOI":"10.1378\/chest.111.6.1603"},{"key":"b38","doi-asserted-by":"crossref","unstructured":"Rosendaal FR, Koster T, Vandenbroucke JP, Reitsma PH. 1995. High risk of thrombosis in patients homozygous for factor V Leiden (activated protein C resistance).Blood85(6):1504\u20138","DOI":"10.1182\/blood.V85.6.1504.bloodjournal8561504"},{"key":"b39","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(94)90286-0"},{"key":"b40","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199806183382502"},{"key":"b41","doi-asserted-by":"publisher","DOI":"10.1055\/s-0038-1657712"},{"key":"b42","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.1996.d01-1496.x"},{"key":"b43","doi-asserted-by":"crossref","unstructured":"Ridker PM, Hennekens CH, Selhub J, et al. 1997. Interrelation of hyperhomocyst(e)inemia, factor V Leiden, and risk of future venous thromboembolism.Circulation95:1777\u201382","DOI":"10.1161\/01.CIR.95.7.1777"},{"key":"b44","doi-asserted-by":"crossref","unstructured":"Cattaneo M, Tsai MY, Bucciarelli P, et al. 1997. A common mutation in the methylenetetrahydrofolate reductase gene (C677T) increases the risk for deepvein thrombosis in patients with mutant factor V (factor V:Q506).Arterioscler. Thromb. Vasc. Biol.17:1662\u201366","DOI":"10.1161\/01.ATV.17.9.1662"},{"key":"b45","doi-asserted-by":"publisher","DOI":"10.1055\/s-0037-1615091"},{"key":"b46","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V86.1.219.bloodjournal861219"},{"key":"b47","doi-asserted-by":"crossref","unstructured":"Zoller B, Holm J, Svensson P, Dahlback B. 1996. Elevated levels of prothrombin activation fragment 1+2 in plasma from patients with heterozygous Arg506 to Gln mutation in the factor V gene (APCresistance) and\/or inherited protein S deficiency.Thromb. Haemost.75:270\u2013 74","DOI":"10.1055\/s-0038-1650259"},{"key":"b48","doi-asserted-by":"crossref","unstructured":"Van Boven HH, Reitsma PH, Rosendaal FR, et al. 1996. Factor V Leiden (FV R506Q) in families with inherited antithrombin deficiency.Thromb. Haemost.75:417\u201321","DOI":"10.1055\/s-0038-1650289"},{"key":"b49","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-126-7-199704010-00005"},{"key":"b50","doi-asserted-by":"crossref","unstructured":"Ridker PM, Hennekens CH, Miletich JP. 1999. G20210A mutation in prothrombin gene and risk of myocardial infarction, stroke and venous thrombosis in a large cohort of US men.Circulation99:999\u2013 1004","DOI":"10.1161\/01.CIR.99.8.999"},{"key":"b51","doi-asserted-by":"publisher","DOI":"10.1055\/s-0037-1615049"},{"key":"b52","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.158.1.89"},{"key":"b53","doi-asserted-by":"publisher","DOI":"10.1055\/s-0037-1615199"},{"key":"b54","doi-asserted-by":"publisher","DOI":"10.1055\/s-0038-1665427"},{"key":"b55","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199903253401201"},{"key":"b56","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199702063360601"},{"key":"b57","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.157.19.2227"},{"key":"b58","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199702063360601"},{"key":"b59","doi-asserted-by":"crossref","unstructured":"Palareti G, Leali N, Coccheri S, et al. 1996. Bleeding complications of oral anticoagulant treatment: an inceptioncohort, prospective collaborative study (ISCOAT).Lancet348:423\u201328","DOI":"10.1016\/S0140-6736(96)01109-9"},{"key":"b60","doi-asserted-by":"crossref","unstructured":"Landefeld CS, Beyth RJ. 1993. Anticoagulant-related bleeding: clinical epidemiology, prediction, and prevention.Am. J. Med.95:315\u201328","DOI":"10.1016\/0002-9343(93)90285-W"},{"key":"b61","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9343(98)00198-3"},{"key":"b62","doi-asserted-by":"publisher","DOI":"10.1016\/0140-6736(92)93285-U"},{"key":"b63","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199506223322501"},{"key":"b64","doi-asserted-by":"crossref","unstructured":"Levine MN, Hirsh J, Gent M, et al. 1995. Optimal duration of oral anticoagulant therapy: a randomized trial comparing four weeks with three months of warfarin in patients with proximal deep vein thrombosis.Thromb. Haemost.74:606\u2013 11","DOI":"10.1055\/s-0038-1649783"},{"key":"b65","doi-asserted-by":"publisher","DOI":"10.1001\/jama.279.6.458"},{"key":"b66","doi-asserted-by":"publisher","DOI":"10.1378\/chest.114.5_Supplement.531S"},{"key":"b67","doi-asserted-by":"crossref","unstructured":"Pabinger I, Kyrle PA, Heistinger M, et al. 1994. The risk of thromboembolism in asymptomatic patients with protein C and protein S deficiency: a prospective cohort study.Thromb. Haemost.71:441\u2013 45","DOI":"10.1055\/s-0038-1642457"},{"key":"b68","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1055\/s-0038-1642480","volume":"71","year":"1994","journal-title":"Thromb. Haemost."},{"key":"b69","doi-asserted-by":"publisher","DOI":"10.1001\/jama.280.7.605"},{"key":"b70","doi-asserted-by":"crossref","unstructured":"Pini M, Aiello S, Manotti C, et al. 1994. Low molecular weight heparin versus warfarin the prevention of recurrence after deep vein thrombosis.Thromb. Haemost.72(2):191\u201397","DOI":"10.1055\/s-0038-1648837"},{"key":"b71","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-125-1-199607010-00001"},{"key":"b72","doi-asserted-by":"crossref","unstructured":"Schulman S. 1997. Optimal duration of oral anticoagulant therapy in venous thromboembolism.Thromb. Haemost.78(1):693\u201398","DOI":"10.1055\/s-0038-1657614"},{"key":"b73","doi-asserted-by":"crossref","unstructured":"Simioni P, Prandoni P, Lensing AWA, et al. 1997. The risk of recurrent venous thromboembolism in patients with an Arg506\u2192Gln mutation in the gene for factor V (factor V Leiden).N. Engl. J. Med.336:399\u2013403","DOI":"10.1056\/NEJM199702063360602"},{"key":"b74","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.92.10.2800"},{"key":"b75","doi-asserted-by":"crossref","unstructured":"Eichinger S, Pabinger I, Stumpflen A, et al. 1997. The risk of recurrent venous thromboembolism in patients with and without factor V Leiden.Thromb. Haemost.77(4):624\u201328","DOI":"10.1055\/s-0038-1656023"},{"key":"b76","doi-asserted-by":"publisher","DOI":"10.1055\/s-0037-1614409"},{"key":"b77","doi-asserted-by":"crossref","unstructured":"Friederich PW, Sanson BJ, Simioni P, et al. 1996. Frequency of pregnancy-related venous thromboembolism in anticoagulant factor-deficient women: implications for prophylaxis.Ann. Intern. Med.125:955\u201360","DOI":"10.7326\/0003-4819-125-12-199612150-00003"},{"key":"b78","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(96)04125-6"},{"key":"b79","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199901073400102"},{"key":"b80","doi-asserted-by":"crossref","unstructured":"Greer IA. 1999. Thrombosis in pregnancy: maternal and fetal issues.Lancet353:1258\u201365","DOI":"10.1016\/S0140-6736(98)10265-9"},{"key":"b81","doi-asserted-by":"crossref","unstructured":"Conard J, Horellou MH, Van Dreden P, et al. 1990. Thrombosis and pregnancy in congenital deficiencies in AT III, protein C, or protein S: study of 78 women.Thromb. Haemost.63:319\u201330","DOI":"10.1055\/s-0038-1645218"},{"key":"b82","doi-asserted-by":"crossref","unstructured":"DeStephano V, Leone G, Mastrangelo S. 1994. Thrombosis during pregnancy and surgery in patients with congenital deficiency of antithrombin III, protein C, protein S.Thromb. Haemost.71:799\u2013 800","DOI":"10.1055\/s-0038-1642528"},{"key":"b83","doi-asserted-by":"crossref","unstructured":"Lindqvist PG, Svensson PJ, Marsal K. 1999. Activated protein C resistance (FV:Q506) and pregnancy.Thromb. Haemost.81:532\u201337","DOI":"10.1055\/s-0037-1614519"},{"key":"b84","doi-asserted-by":"crossref","unstructured":"Rosendaal FR. 1993. Venous thrombosis: a multicausal disease.Lancet353:1167\u201373","DOI":"10.1016\/S0140-6736(98)10266-0"}],"container-title":["Annual Review of Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.annualreviews.org\/doi\/pdf\/10.1146\/annurev.med.51.1.169","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,13]],"date-time":"2021-10-13T23:52:03Z","timestamp":1634169123000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.annualreviews.org\/doi\/10.1146\/annurev.med.51.1.169"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2000,2]]},"references-count":84,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2000,2]]}},"alternative-id":["10.1146\/annurev.med.51.1.169"],"URL":"https:\/\/doi.org\/10.1146\/annurev.med.51.1.169","relation":{},"ISSN":["0066-4219","1545-326X"],"issn-type":[{"value":"0066-4219","type":"print"},{"value":"1545-326X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2000,2]]}}}